| 1. |
|
|
| 2. |
- Cardenas, EI, et al.
(författare)
-
IL-26 in asthma and COPD
- 2022
-
Ingår i: Expert review of respiratory medicine. - : Informa UK Limited. - 1747-6356 .- 1747-6348. ; 16:3, s. 293-301
-
Tidskriftsartikel (refereegranskat)
|
|
| 3. |
- Ekström, Magnus, et al.
(författare)
-
Patient reported outcome measures in chronic obstructive pulmonary disease : Which to use?
- 2016
-
Ingår i: Expert Review of Respiratory Medicine. - Oxfordshire, United Kingdom : Taylor & Francis. - 1747-6348 .- 1747-6356. ; 10:3, s. 351-362
-
Forskningsöversikt (refereegranskat)abstract
- Patient-reported outcomes (PROs), such as symptoms and perceived health status, are essential in chronic obstructive pulmonary disease (COPD) for determining disease severity, impact on daily life, effect of treatment and recovery from exacerbations. This field has evolved rapidly and there are a plethora of instruments assessing different PROs. The aim of this review is to provide an understanding of the concept of PROs in COPD. The PROs reflect important aspects of COPD which have a direct impact on daily life. Common symptoms such as dyspnea, cough, phlegm, anxiety, fatigue, and pain and as well as physical function and the risk for and occurrence of acute exacerbations should be assessed both in the clinic and in research. Besides impact on daily life, some of the PROs are related to disease progress and mortality. Construction of composite variables including different disease specific and generic PROs provide a general estimation of health status.
|
|
| 4. |
- Högman, Marieann, et al.
(författare)
-
Utilising exhaled nitric oxide information to enhance diagnosis and therapy of respiratory disease : current evidence for clinical practice and proposals to improve the methodology
- 2017
-
Ingår i: Expert Review of Respiratory Medicine. - : Taylor & Francis Group. - 1747-6348 .- 1747-6356. ; 11:2, s. 101-109
-
Forskningsöversikt (refereegranskat)abstract
- Introduction: A non-invasive tool to diagnose respiratory diseases and to follow treatment has long been looked-for. Exhaled nitric oxide (NO) is a promising marker of inflammation in asthma but nearly 25-years of research has shown that it works in only certain endotypes of asthma. The modelling of NO dynamics of the lung can give more information than a single FENO value.Areas covered: The estimation of the NO production in the conducting airways and in the gasexchange area has given new insight of the NO production in diseases beyond asthma. In thisarticle, we discuss the importance of methodology for NO measurement in the exhaled breath and the indication of applying this technique to detect respiratory disorders. This narrative review is an attempt to examine and discuss the physiological basis underlying exhaled NO measurements and the clinical evidence of the usefulness of this method in asthma and various other respiratory disorders.Expert commentary: Estimation of the NO parameters would aid in our understanding of the NOdynamics of the lung and thereby give more knowledge how to interpret the measured FENO value in clinical practice.
|
|
| 5. |
|
|
| 6. |
|
|
| 7. |
- Lundbäck, Bo, 1948, et al.
(författare)
-
Is asthma prevalence still increasing?
- 2016
-
Ingår i: Expert Review of Respiratory Medicine. - : Informa UK Limited. - 1747-6348 .- 1747-6356. ; 10:1, s. 39-51
-
Forskningsöversikt (refereegranskat)abstract
- Increased awareness of asthma in society and altered diagnostic practices makes evaluation of data on prevalence change difficult. In most parts of the world the asthma prevalence seems to still be increasing. The increase is associated with urbanization and has been documented particularly among children and teenagers in urban areas of middle- and low-level income countries. Use of validated questionnaires has enabled comparisons of studies. Among adults there are few studies based on representative samples of the general population which allow evaluation of time trends of prevalence. This review focuses mainly on studies of asthma prevalence and symptoms among adults. Parallel with increased urbanization, we can assume that the increase in asthma prevalence in most areas of the world will continue. However, in Australia and North-West Europe studies performed, particularly among children and adolescents, indicate that the increase in asthma prevalence may now be leveling off.
|
|
| 8. |
|
|
| 9. |
|
|
| 10. |
- Nilsson, J Lars G., et al.
(författare)
-
Asthma/COPD drugs reflecting disease prevalence, patient adherence and persistence
- 2009
-
Ingår i: Expert Review of Respiratory Medicine. - : Informa UK Limited. - 1747-6348 .- 1747-6356. ; 3:1, s. 93-101
-
Tidskriftsartikel (refereegranskat)abstract
- The aim of this review is to discuss the methodological issues involved in using pharmacy-record databases of drug sales in pharmacoepidemiology and to illustrate the usefulness of such data in estimating disease prevalence, patient adherence and persistence to therapy. Recent studies show that asthma/chronic obstructive pulmonary disease (COPD) prevalence increases with age. The volume of acquired asthma/COPD drugs per patient also increases with age and was approximately 2.5-times higher for patients aged 60-69 years compared with patients aged 20-29 years. Despite this, there is a comparatively low interest in asthma/COPD research involving elderly individuals. Published asthma/COPD-prevalence data and drug-treatment-prevalence data correspond reasonably well. Short- as well as long-term studies on drug acquisition indicate that approximately a third of patients have drugs available to cover at least 80% of the prescribed treatment time. Only approximately a tenth of the patients acquired steroids or steroid combinations, corresponding to one daily defined dose per day over a 5-year treatment period. It is probable that asthma/COPD is undertreated in all age groups.
|
|
